| If you have a story to submit, let us know. We want to highlight information about the Society, it's research or researchers. |
September 2003
The Leukemia & Lymphoma Society is highlighted in a story about a U.S. Department of Defense chronic myelogenous leukemia research program.
June 2003
Alan Kinniburgh, Ph.D., Vice President of Research Administration, The Leukemia & Lymphoma Society, is quoted in an article about the effectiveness of a seven-drug "cocktail" against Hodgkin lymphoma.
May 2003
Marshall Lichtman, M.D, Executive Vice President, Research & Medical Programs, The Leukemia & Lymphoma Society, was quoted in this story about exciting blood cancer research taking place at the University of Montreal, Canada. The lead researcher, Guy Sauvageau, M.D., Ph.D., is a Society-funded Scholar.
April 2003
Dr. Lichtman is the featured expert in this April 28 ABCNEWS.com piece about the increasing uses of GleevecTM in treating chronic myelogenous leukemia and other cancers.
March 2003
Drug Shows Promise in At Least 4 Cancers, New York Times (March 27)
Alan Kinniburgh, Ph.D., Vice President of Research Administration, The Leukemia & Lymphoma Society, is quoted in an article about the growing use of Gleevec in treating several forms of cancer.
October 2002
A new cancer-killing "cocktail" shows promise in laboratory studies as an effective way to attack acute myelogenous leukemia (AML).
June 2002
A gene screening test that finds molecular signatures of blood cancer can give doctors a fix on which patients are likely to do well in treatment - and which will probably die despite it.
A protein known to be involved in the body's immune system was found unexpectedly in cancerous cells taken from breast and colon tumors and could become a surprising new basis for anti-cancer drugs, researchers announced Monday.
Two recent studies of households in England, Scotland and Wales suggest that high levels of naturally-occurring radiation, such as radon, do not translate into a greater risk of cancer in children who live in those homes.
March 2002
Considering that less than a third of people who need a bone marrow transplant find a suitable match, new groundbreaking research on mice offers the potential to save the lives of thousands of people each year.
February 2002
The cancer drug Gleevec is living up to its billing in patients with leukemia who have failed to respond well to conventional therapy. In fact, doctors say, less than a year after winning regulatory approval Gleevec has become the treatment of choice for people with chronic myelogenous leukemia.
print page
email page
